Cardiometabolic Risk of Obese Subjects: Cross-sectional Study (MiRNome)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Enrolling

Conditions: Genetics; Cardiovascular Risk; Obesity and Obesity-related Medical Conditions

Study type: Observational

Funder types: Other

Identifiers

NCT06714058

MiRNome

Details and patient eligibility

About

experimental study with analysis on tissues. This study aims to study cardiometabolic risk from a genetic, clinical, instrumental and laboratory point of view in a population of subjects with obesity.

Full description

Compared to normal clinical practice, if you decide to participate in the study you will be asked to:

1. allow the collection of an additional study-specific amount of blood as part of a blood sample already provided for by clinical practice during the dietetic visit; The sample will be used to perform the genetic and laboratory analyses required by the study.
2. Undergo an additional study-specific visit within one month of the dietetic visit. will be subjected to the measurement of the degree of vascular aging and the evaluation of the health of his/her arteries, through non-invasive examinations.

Enrollment: 240 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age > 18 years

  • BMI > 30 Kg/m2
  • In primary prevention for cardiovascular disease
  • Ability to communicate, make themselves understood and adhere to study-specific procedures
  • Willingness to participate in the study and obtain informed consent

Exclusion criteria

• Patients already enrolled by the Research Units involved in the enrolment
• Glycated hemoglobin level > 55 mmol/L
• Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes
• Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS>8)
• Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies
• Patients suffering from systemic inflammatory or oncological diseases
• Patients on active treatment with GLP-1 analogues
• Pregnancy and breastfeeding
• Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.